Cases & Deals

  • Home
  • Practices
  • Stallergenes Greer plc acquired by Waypoint for approximately €110 million (US$124 million)

Share

Stallergenes Greer plc acquired by Waypoint for approximately €110 million (US$124 million)

May 2019

Client(s) Stallergenes Greer plc

Jones Day advised Stallergenes Greer plc in the recommended cash acquisition by Ares Life Sciences I S.à r.l. (Waypoint) of the entire issued, and to be issued, ordinary share capital of Stallergenes Greer not held directly or indirectly by Waypoint by way of a scheme of arrangement for approximately €110 million (US$124 million).

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.